iSpecimen

iSpecimen Net Debt / EBITDA

The Net Debt to EBITDA of iSpecimen (ISPC) as of Nov 5, 2026 is 0.74. In the previous year, Net Debt to EBITDA was 0.12 — a change of 498.50% (higher).

Net Debt / EBITDA

0.74

YoY

498.50%

Last updated:

Net Debt to EBITDA of iSpecimen is 2025 0.74 . Net Debt to EBITDA of iSpecimen was 2024 0.12 . It decreases by 498.50% higher compared to the previous year.

The iSpecimen Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
-1.37 USD
Jan 1, 2019
-3.33 USD
Jan 1, 2020
-4.72 USD
Jan 1, 2021
3.55 USD
Jan 1, 2022
1.49 USD
Jan 1, 2023
0.43 USD
Jan 1, 2024
0.12 USD
Jan 1, 2025
0.74 USD
The iSpecimen Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.74+498.50%
0.12-71.42%
0.43-71.03%
1.49-58.08%
3.55-175.05%
-4.72+41.66%
-3.33+143.26%
-1.37—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iSpecimen Stock analysis

What does iSpecimen do? iSpecimen, Inc. generates revenue through its iSpecimen Marketplace platform, which connects healthcare providers with biospecimens to researchers in biopharmaceutical, in vitro diagnostic (IVD), and government/academic sectors. The platform consolidates biospecimen procurement by offering a single online marketplace where healthcare supply partners provide de-identified healthcare data, enabling researchers to search, manage workflows, and access administrative tools. Biopharmaceutical companies, IVD firms, and academic institutions purchase access to the platform’s data and services to accelerate medical discovery and streamline procurement processes. The company’s functional areas—search, workflow, data, and administration and reporting—support these transactions through integrated administrative and compliance management for all users. The iSpecimen Marketplace platform serves biopharmaceutical companies, in vitro diagnostic (IVD) companies, and government/academic institutions by providing a centralized hub for biospecimen procurement. Healthcare providers supplying biospecimens use the platform to list their collections, while researchers from the target sectors access the data for their studies. The platform’s de-identified healthcare data, compiled from healthcare supply partners, is a key asset that drives transactions. Administrative and reporting functions within the platform streamline operations for both suppliers and researchers, reducing manual effort and improving compliance. iSpecimen, Inc. monetizes its platform by facilitating connections between biospecimen suppliers and researchers across biopharmaceutical, IVD, and academic sectors. The company’s revenue comes from transactions and services provided through the iSpecimen Marketplace, which includes search capabilities, workflow management, data access, and administrative support. Healthcare supply partners contribute de-identified healthcare data to the platform, which researchers use to identify and procure necessary biospecimens for medical research and development. iSpecimen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iSpecimen stock

Net Debt to EBITDA of iSpecimen is 0.74 in 2025.

Net Debt to EBITDA of iSpecimen changed from 0.12 to 0.74, representing a 498.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA iSpecimen since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's iSpecimen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — iSpecimen

All Key Metrics — iSpecimen